Kelly N. Kerr
FDA investigator
Appears on 2 documents from 2019 to 2020, mostly at sites in Pennsylvania. Most often cites general responsibilities of investigators (21 CFR 312.60).
- 2
- Documents on file
- 1.0
- Observations per 483
- 2019
- First seen
- 2020
- Most recent
What they cite most
From 2 observations- 21 CFR 312.60General responsibilities of investigators1
- 21 CFR 58.130Conduct of a nonclinical laboratory study1
Activity by year
2019: 1, 2020: 1
Where
Pennsylvania 2
Often inspects with
Is Kelly N. Kerr coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2020-09-28 | 483 Sigrid Blome-EberweinSep 28, 2020 · Allentown, Pennsylvania | Allentown, Pennsylvania | 1 | |
| 2019-04-30 | 483 Merck Sharp & Dohme LLCApr 30, 2019 · West Point, Pennsylvania | West Point, Pennsylvania | 1 |
About this profile
What does Kelly N. Kerr inspect?
Kelly N. Kerr appears on 2 documents on file covering 2 sites, mostly in Pennsylvania.
What do they cite most often?
21 CFR 312.60 (general responsibilities of investigators), followed by 21 CFR 58.130.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Kelly N. Kerr is dated Sep 28, 2020.